미국의 염증성 장질환 치료 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 약제 클래스별, 투여 경로별, 유통 채널별, 지역별, 부문 예측(2025-2030년)

U.S. Inflammatory Bowel Disease Treatment Market Growth & Trends:

The U.S. inflammatory bowel disease treatment market size is anticipated to reach USD 15.70 billion by 2030 and is projected to grow at a CAGR of 2.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of ulcerative colitis and Crohn's disease across the U.S. is anticipated to drive market growth in the forecast period. A combination of genetic predisposition, immune system dysfunction, environmental factors, gut microbiota imbalance, and lifestyle factors likely influence the development of inflammatory bowel disease (IBD). According to an article published in 2023, inflammatory bowel disease is a relatively common chronic condition affecting >0.7% of Americans and is most prevalent in the Northeastern region. This growing patient population necessitates advanced treatment options, driving the market growth.

The Crohn's & Colitis Foundation works toward enhancing product development to improve the quality of life of patients suffering from inflammatory bowel illnesses. The foundation has launched these ventures, a dedicated funding system to support product-oriented research and development.

In September 2023, Takeda announced the FDA's acceptance of the biologics license application (BLA) for the subcutaneous administration of ENTYVIO (vedolizumab) to treat Crohn's disease. Regulatory approvals pave the way for new medications, biologics, and devices to enter the market. This can lead to a broader range of treatment options for patients with IBD, potentially improving treatment outcomes and quality of life.

U.S. Inflammatory Bowel Disease Treatment Market Report Highlights:

• Based on type, the Crohn's disease segment dominated the market in 2024 with the largest revenue share. This large share is due to the requirement for more treatment options and advancements due to the chronic inflammatory nature of Crohn's disease, which affects the gastrointestinal tract and causes symptoms such as abdominal pain, diarrhea, weight loss, and fatigue.
• Based on drug class, the TNF inhibitors segment accounted for the largest market revenue share in 2024 due to their effectiveness in managing the symptoms and reducing inflammation.
• Based on route of administration, the injectable segment held the largest market share in 2024. Injectable medications, such as biologics and biosimilars, are designed to target specific proteins or cells involved in the inflammatory process of inflammatory bowel disease.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Drug Class
  • 1.2.3. Route of Administration
  • 1.2.4. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Inflammatory Bowel Disease Treatment Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
    • 3.3.3.1. Phase 1
    • 3.3.3.2. Phase 2
    • 3.3.3.3. Phase 3
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. U.S. Inflammatory Bowel Disease Treatment market: Type Business Analysis

• 4.1. Type Market Share, 2024 & 2030
• 4.2. Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. Crohn's Disease
  • 4.4.1. Crohn's Disease Market, 2018 - 2030 (USD Million)
• 4.5. Ulcerative Colitis
  • 4.5.1. Ulcerative Colitis Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Inflammatory Bowel Disease Treatment market: Drug Class Business Analysis

• 5.1. Drug Class Market Share, 2024 & 2030
• 5.2. Drug Class Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
• 5.4. Aminosalicylates
  • 5.4.1. Aminosalicylates Market, 2018 - 2030 (USD Million)
• 5.5. Corticosteroids
  • 5.5.1. Corticosteroids Market, 2018 - 2030 (USD Million)
• 5.6. TNF Inhibitors
  • 5.6.1. TNF Inhibitors Market, 2018 - 2030 (USD Million)
• 5.7. IL inhibitors
  • 5.7.1. IL inhibitors Market, 2018 - 2030 (USD Million)
• 5.8. Anti-integrin
  • 5.8.1. Anti-integrinMarket, 2018 - 2030 (USD Million)
• 5.9. JAK inhibitors
  • 5.9.1. JAK inhibitors Market, 2018 - 2030 (USD Million)
• 5.10. Others
  • 5.10.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. U.S. Inflammatory Bowel Disease Treatment market: Route of Administration Business Analysis

• 6.1. Route of Administration Market Share, 2024 & 2030
• 6.2. Route of Administration Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 6.4. Oral
  • 6.4.1. Oral Market, 2018 - 2030 (USD Million)
• 6.5. Injectable
  • 6.5.1. Injectable Market, 2018 - 2030 (USD Million)

Chapter 7. U.S. Inflammatory Bowel Disease Treatment market: Distribution Channel Business Analysis

• 7.1. Distribution Channel Market Share, 2024 & 2030
• 7.2. Distribution Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 7.4. Hospital Pharmacy
  • 7.4.1. Hospital Pharmacy Market, 2018 - 2030 (USD Million)
• 7.5. Retail Pharmacy
  • 7.5.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
• 7.6. Online Pharmacy
  • 7.6.1. Online Pharmacy Market, 2018 - 2030 (USD Million)

Chapter 8. U.S. Inflammatory Bowel Disease Treatment market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
• 8.4. West.
  • 8.4.1. Key Country Dynamics
  • 8.4.2. Target Disease Prevalence
  • 8.4.3. Regulatory Framework
  • 8.4.4. Reimbursement Framework
  • 8.4.5. West U.S. Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Midwest
  • 8.5.1. Key Country Dynamics
  • 8.5.2. Target Disease Prevalence
  • 8.5.3. Regulatory Framework
  • 8.5.4. Reimbursement Framework
  • 8.5.5. Midwest U.S. Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Northeast
  • 8.6.1. Key Country Dynamics
  • 8.6.2. Target Disease Prevalence
  • 8.6.3. Regulatory Framework
  • 8.6.4. Reimbursement Framework
  • 8.6.5. Northeast U.S. Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.7. Southwest
  • 8.7.1. Key Country Dynamics
  • 8.7.2. Target Disease Prevalence
  • 8.7.3. Regulatory Framework
  • 8.7.4. Reimbursement Framework
  • 8.7.5. Southwest U.S. Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.8. Southeast
  • 8.8.1. Key Country Dynamics
  • 8.8.2. Target Disease Prevalence
  • 8.8.3. Regulatory Framework
  • 8.8.4. Reimbursement Framework
  • 8.8.5. Southeast U.S. Inflammatory Bowel Disease Treatment Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Biogen
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Novartis AG
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Eli Lilly and Company
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. UCB S.A.
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Merck & Co., Inc.
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. Johnson & Johnson Services, Inc.
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives